

# EXHIBIT A

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449-PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 12

**Complete if Known**

Application Number	10/565,484
Filing Date	January 17, 2006
First Named Inventor	CHEUNG, Nai-Kong V.
Art Unit	1623
Examiner Name	Eric Olson
Attorney Docket Number	639-C-PT-US

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (If known)			
	1	US- 7,030,101	04-18-2006	Pavliak et al.	
	2	US- 6,143,731	11-07-2000	Jamas et al.	
	3	US- 6,117,850	09-12-2000	Patchen et al.	
	4	US- 6,020,324	02-01-2000	Jamas et al.	
	5	US- 5,817,643	10-06-1998	Jamas et al.	
	6	US- 5,811,542	09-22-1998	Jamas et al.	
	7	US- 5,804,199	09-08-1998	Aasjord et al.	
	8	US- 5,783,569	07-21-1998	Jamas et al.	
	9	US- 5,726,023	03-10-1998	Cheever et al.	
	10	US- 5,702,719	12-30-1997	Byron A. Donzis	
	11	US- 5,696,079	12-09-1997	Lane et al.	
	12	US- 5,622,940	04-22-1997	Gary Ostroff	
	13	US- 5,607,677	03-04-1997	Jamas et al.	
	14	US- 5,576,015	11-19-1996	Byron A. Donzis	
	15	US- 5,532,223	07-02-1996	Jamas et al.	
	16	US- 5,037,972	08-06-1991	Jamas et al.	
	17	US- 4,992,540	02-12-1991	Jamas et al.	
	18	US- 4,926,094	05-15-1990	Bondeson et al.	
	19	US- 4,900,722	02-13-1990	Williams et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>4</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (If known)				
	40	WO 2007/84661	07-26-2007	Steen-Kulering Institute for Cancer Research		
	41	WO 2006/119395	11-09-2006	Biopolymer Engineering		
	42	WO 2006/85895	08-17-2006	Biopolymer Engineering and Univ. Louisiana		
	43	WO 2005/49044	06-02-2005	Laboratoires Goemar SA		
	44	WO 2005/27938	03-31-2005	Laboratoires Goemar SA		
	45	WO 2005/27936	03-31-2005	Laboratoires Goemar		

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 605. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 12 of 12

## Complete if Known

Application Number 10/565,484  
Filing Date January 17, 2006  
First Named Inventor CHEUNG, Nai-Kong V.  
Art Unit 1623  
Examiner Name Eric Olson  
Attorney Docket Number 639-C-PCT-US

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	20	US- 4,705,780	11-10-1987	Massot et al.	
	21	US- 4,454,289	06-12-1984	Nakajima et al.	
	22	US- 4,343,784	08-10-1982	Massot et al.	
	23	US- 4,251,519	02-17-1981	Robbins et al.	
	24	US- 3,975,553	08-17-1976	Henri Griffon	
	25	US- 2007/134259	06-14-2007	Bundle et al.	
	26	US- 2007/59310	03-15-2007	Steven J. Karel	
	27	US- 2007/20232	01-25-2007	Rossignol et al.	
	28	US- 2007/263355	11-23-2006	Quan et al.	
	29	US- 2006/185700	07-27-2006	Ostroff et al.	
	30	US- 2006/180766	07-20-2006	Nai-Kong V. Cheung	
	31	US- 2006-0020128	01-26-2006	Nai-Kong V. Cheung	
	32	US- 2006/09419	01-12-2006	Ross et al.	
	33	US- 2005/208079	09-22-2005	Cassone et al.	
	34	US- 2005/118187	06-02-2005	Baofa Yu	
	35	US- 2002/119928	08-29-2002	Bill H. McAnally	
	36	US- 2002/44919	04-18-2002	Baofa Yu	
		US-			
		US-			

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	46	WO 2004/30613	03-16-2004	University of Louisville Research		
	47	WO 2003/54077	07-03-2003	Coapro Inc.		
	48	WO 2003/004507	01-16-2003	Research Center for Eco-Environmental Sci.		
	49	WO 2002/58711	08-01-2002	Roan-Kettering Institute for Cancer Research		
	50	WO 2001/80807	11-01-2001	Laboratoires Gomar SA		
	51	WO 2001/68105	11-20-2001	Eurand Pharmaceutical		

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

(Use as many sheets as necessary)

Sheet	3
-------	---

of

12

Application Number	10/565,484
Filing Date	January 17, 2006
First Named Inventor	CHEUNG, Nai-Kwong
Art Unit	1623
Examiner Name	Eric Olson
Attorney Docket Number	639-C-PCT-US

[illegible][illegible]

Examiner  
Signature

Date  
Considered

\* EXAMINER: Initiate if reference considered, whether or not citation is in conformance with MPEP 909. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3) <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

4

of

12

## Complete if Known

Application Number	10/565,484
Filing Date	January 17, 2006
First Named Inventor	CHEUNG, Nai-Kong V.
Art Unit	1623
Examiner Name	Eric Olson
Attorney Docket Number	639-C-PCT-US

## OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	37	Supplementary Partial European Search Report, February 5, 2008, for European Application No. EP 02 70 7502, filed August 4, 2003 for SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH.	
	38	PCT International Search Report for SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH. September 26, 2007, Int'l Application No. PCT/US07/01427 (Atty. Dkt. #639-F-PCT), Filed January 18, 2007.	
	39	PCT Written Opinion of the International Searching Authority for SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, September 26, 2007, Int'l Application No. PCT/US07/01427 (Atty. Dkt. #639-F-PCT), Filed January 18, 2007.	
	56	Chinese Office Action, May 9, 2008, for SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, Chinese Application No. 200480020358.6 (Atty. Dkt. #639-C-PCT-CN), Filed January 16, 2006, corresponding to PCT/US04/23099.	
	57	U.S. Office Action, March 5, 2008, for Nai-Kong V. CHEUNG, U.S. Serial No. 11/334,763 (Atty. Dkt. #639-E-US), Filed January 17, 2006.	
	58	U.S. Office Action, August 7, 2007, for Nai-Kong V. CHEUNG, U.S. Serial No. 11/218,044, Filed August 31, 2005. (Atty. Dkt. #639-BZ-PCT-US).	
	59	U.S. Office Action, August 7, 2007, for Nai-Kong V. CHEUNG, U.S. Serial No. 10/621,027, Filed July 16, 2003. (Atty. Dkt. #639-B-PCT-US).	
	60	U.S. Office Action, January 4, 2007, for Nai-Kong V. CHEUNG, U.S. Serial No. 10/621,027, Filed July 16, 2003. (Atty. Dkt. #639-B-PCT-US).	
	61	U.S. Office Action, November 22, 2006, for Nai-Kong V. CHEUNG, U.S. Serial No. 11/218,044, Filed August 31, 2005. (Atty. Dkt. #639-BZ-PCT-US).	
	62	U.S. Office Action, March 10, 2008, for Nai-Kong V. CHEUNG, U.S. Serial No. 11/218,044, Filed August 31, 2005. (Atty. Dkt. #639-BZ-PCT-US).	

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

† Applicant's unique citation designation number (optional). ‡ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

5

of

12

**Complete if Known**

Application Number	10/565,484
Filing Date	January 17, 2006
First Named Inventor	CHEUNG, Nai-Kong V.
Art Unit	1623
Examiner Name	Eric Olson
Attorney Docket Number	639-C-PCT-US

**OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	63	U.S. Office Action, March 6, 2006, for Nai-Kong V. CHEUNG, U.S. Serial No. 10/621,027, Filed July 16, 2003. (Atty. Dkt. #639-B-PCT-US).	
	64	U.S. Office Action, July 13, 2005, for Nai-Kong V. CHEUNG, U.S. Serial No. 10/621,027, Filed July 16, 2003. (Atty. Dkt. #639-B-PCT-US).	
	65	U.S. Office Action, December 17, 2004, for Nai-Kong V. CHEUNG, U.S. Serial No. 10/621,027, Filed July 16, 2003. (Atty. Dkt. #639-B-PCT-US).	
	66	Bela Glucan Health Center webpage, November 10, 2000, "PLEURAN—Beta-1,3/1-6-Glucan," <a href="http://www.glucan.com/therapy/therapy.com">http://www.glucan.com/therapy/therapy.com</a> .	
	67	1999 The Merck Manual of Diagnosis and Therapy, 397-398, 948-949, 1916, 1979-1981.	
	68	ADACHI et al., 1990, "Macrophage Activation in Vitro by Chemically Cross-Linked (1-3)- $\beta$ -D-Glucans", Chem. Pharm. Bull., 38(4):988-992.	
	69	AZUMA, Ichiro, "Development of Immunostimulants in Japan", Immunostimulants: Now and Tomorrow, 41-56.	
	70	BERGMAN et al., 1999, "Treatment of Neoplastic Meningeal Xenografts by Intraventricular Administration of an Antiganglioside Monoclonal Antibody, 3F8," Int. J. Cancer, 82:538-548	
	71	BLUHM et al., 1977, "The triple helical structure of lentinan, a linear $\beta$ -(1 $\rightarrow$ 3)-D-glucan", Can J Chem, 55:293-299.	
	72	BOGWALD et al., 1982, "The Cytotoxic Effect of Mouse Macrophages Stimulated in Vitro by a $\beta$ -1,3-D-Glucan from Yeast Cell Walls", Scandinavian Journal of Immunology, 15:297-304.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

6

of

12

## Complete if Known

Application Number	10/565,484
Filing Date	January 17, 2006
First Named Inventor	CHEUNG, Nai-Kong V.
Art Unit	1623
Examiner Name	Eric Olson
Attorney Docket Number	639-C-PCT-US

## OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	73	BOHN, J.A., and BeMiller, J.N., 1995, "(1→3)-β-Glucans as biological response modifiers: a review of structure-functional activity relationships," Carbohydrate Polymers, 28:3-14	
	74	BOWERS et al., 1989, "Glucan Enhances Survival in an Intraabdominal Infection Model", Journal of Surgical Research, Vol 47(2):183-188	
	75	CAPURRO et al., 1998, "FC-2.15, a monoclonal antibody active against human breast cancer, specifically recognizes Lewis x hapten," Cancer Immunol. Immunother., 45:334-339	
	76	CHEUNG, N.-K. V., et al., 2002, "Quantitation of GD2 Synthase mRNA by Real-Time Reverse Transcription-Polymerase Chain Reaction - Utility in Bone Marrow Purging of Neuroblastoma by Anti-GD2 Antibody 3F8," Cancer, 94:3042-3048	
	77	CHEUNG, N.-K. V., et al., June 1985, "Monoclonal Antibodies to a Glycolipid Antigen on Human Neuroblastoma Cells," Canc. Res., 45:2642-2649	
	78	CHIHARA et al., 1970, "Fractionation and purification of the polysaccharides with Marked Antitumor Activity, Especially Lentinan, from Lentinus edodes (Berk.) Sing. (an Edible Mushroom)", Cancer Res, 30:2776-2781	
	79	CHIHARA et al., 1981, "The antitumor polysaccharide Lentinan: an overview", Manipulation of Host Defence Mechanisms, 1-16	
	80	CHIHARA et al., 1982, "Current Status and Perspectives of Immunomodulators of Microbial Origin", International Journal of Tissue Reactions, 4:207-225	
	81	DAMGE et al., December 1996, "Intestinal absorption of PLAGA microspheres in the rat," J. Anat., 189:491-501	
	82	D'AMICO et al., 2000, "Molecular Biologic Substaging of Stage I Lung Cancer According to Gender and Histology," Ann. Thorac. Surg., 69:882-886	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.  
This collection of information is required by 37 CFR 1.96. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

7

of

12

**Complete if Known**

Application Number	10/565,484
Filing Date	January 17, 2006
First Named Inventor	CHEUNG, Nai-Kong V.
Art Unit	1623
Examiner Name	Eric Olson
Attorney Docket Number	639-C-PCT-US

**OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	83	DAVID et al., 1996, "Growth arrest of solid human neuroblastoma xenografts in nude rats by natural IgM from healthy humans," Nature Medicine, 2:686-689	
	84	DI LUZIO et al., 1985, "Glucans as Immunomodulators", Advances in Immunopharmacology, Pergamon Press, NY, 369-375	
	85	DI LUZIO et al., 1980, "Comparative Evaluation of the Tumor Inhibitory and Antibacterial Activity of Solubilized and Particulate Glucan", Recent Results in Cancer Research, 75:165-172	
	86	DI LUZIO, Nicholas R., 1985, "Update on the Immunomodulating Activities of Glucans", Springer Seminars in Immunopathology, 8:387-400	
	87	DI LUZIO, Nicholas R., 2003, "Immunopharmacology of glucan: a broad spectrum enhancer of host defense mechanisms", T.I.P.S., 344-347	
	88	ENGLER et al., April 1, 2001, "A Novel Metastatic Animal Model Reflecting the Clinical Appearance of Human Neuroblastoma: Growth Arrest of Orthotopic Tumors by Natural, Cytotoxic Human Immunoglobulin M Antibodies," Cancer Research 61:2968-2973	
	89	FLORENCE A., 1997, "The oral absorption of micro- and nanoparticulates: Neither exceptional nor unusual," Pharmaceutical Research, 14(3):259-265	
	90	FURUE et al., 1985, "Clinical evaluation of schizophyllan (SPG) in advanced gastric cancer (the second report): a randomized controlled study," Gan To Kagaku Ryoho, 12: 1272-1277	
	91	HAMURO et al., 1971, "The significance of the higher structure of the polysaccharides lentinan and pachyman with regard to their antitumor activity", Chem. Biol. Interactions, 3:69-71	
	92	HAMURO et al., 1978, "Solid phase activation of alternative pathway of complement by $\beta$ -1,3-glucans and its possible role for tumour regressing activity", Immunology, 34:695-705	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

8

of

12

## Complete if Known

Application Number	10/565,484
Filing Date	January 17, 2006
First Named Inventor	CHEUNG, Nai-Kong V.
Art Unit	1623
Examiner Name	Eric Olson
Attorney Docket Number	639-C-PCT-US

## OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	93	HARADA et al., 1997, "Oral Administration of PSK can Improve the Impaired Anti-Tumor CD4+ T-Cell Response in Gut-Associated Lymphoid Tissue (GALT) of Specific-Pathogen-Free Mice," Int. J. Cancer, 70:362-372	
	94	HELLSTROM, I. et al., September 1986, "Antitumor effects of L6, and IgG2a antibody that reacts with most human carcinomas," Proc. Natl. Acad. Sci. USA, 83:7059-7063	
	95	HERRE et al., February 2004, "Dectin-1 and its role in the recognition of $\beta$ -glucans by macrophages," Mol. Immunol. 40(12):869-876	
	96	HERRERA et al., 2000, "Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro," Leukemia, 14:853-858	
	97	JAMAS et al., 1990, "Spectral Analysis of Glucan Produced by Wild-Type and Mutant Saccharomyces cerevisiae," Carbohydrate Polymers, 13:207-219	
	98	JANI et al., December 1990, "Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency," J. Pharm. Pharmacol., 42:821-826	
	99	KERNODLE et al., March 1998, "Prophylactic Anti-Infective Activity of Poly(1- $\beta$ -D-Glucopyranosyl(1-3)- $\beta$ -D-Glucopyranose Glucan in a Guinea Pig Model of Staphylococcal Wound Infection," Antimicrobial Agents and Chemotherapy, 42(3):545-549	
	100	KIM, Y.-S., et al., October 20, 2000, "Gram-negative Bacteria-binding Protein, a Pattern Recognition Receptor for Lipopolysaccharide and $\beta$ -1,3-Glucan That Mediates the Signaling for the Induction of Innate Immune Genes in Drosophila melanogaster Cells," J. Biol. Chem., 275(42):32721-32727	
	101	KIRBY et al., 1981, "Oat-bran intake selectively lowers serum low-density lipoprotein cholesterol concentrations of hypercholesterolemic men," American Journal of Clinical Nutrition, 34:824-829	
	102	KOMATSU et al., 1975, "Influence of Schizophyllan, Streptomycin and Rifampicin on Histopathological changes in mice infected with Tubercle Bacilli," Japanese Journal of Antibiotics, XXVII(4):549-557. (English abstract included)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 9 of 12

## Complete if Known

Application Number	10/565,484
Filing Date	January 17, 2006
First Named Inventor	CHEUNG, Nai-Kong V.
Art Unit	1623
Examiner Name	Eric Olson
Attorney Docket Number	639-C-PCT-US

## OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	103	KOTERA, Y., et al., June 1, 1994, "Humoral Immunity against a Tandem Repeat Epitope of Human Mucin MUC-1 in Sera from Breast, Pancreatic, and Colon Cancer Patients," Cancer Res., 54:2856-2860	
	104	MAEDA et al., 1971, "Lentianin, a new immune-accelerator of cell-mediated responses", Nature, 229:634	
	105	MALONEY et al., September 15, 1997, "IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma," Blood, 90(6):2188-2195	
	106	MATZINGER, P., 1994, "Tolerance, Danger, and the Extended Family," Annu. Rev. Immunol., 12:991-1045	
	107	MAYELL M., February 2001, "Maitake Extracts and Their Therapeutic Potential – A Review," Altern. Med. Rev., 6(1):48-60	
	108	MENDELSON et al., 1988, "Monoclonal Antibodies Against the Receptor for Epidermal Growth Factor as Potential Anticancer Agents," Cellular and Molecular Biology of Tumors and Potential Clinical Applications, 307-312	
	109	MENDELSON, J., December 1997, "Epidermal Growth Factor Receptor Inhibition by a Monoclonal Antibody as Anticancer Therapy," Clin. Cancer Res., 3:2703-2707	
	110	NAKAO et al., 1983, "Clinical evaluation of schizophyllan (SPG) in advanced gastric cancer—a randomized comparative study by an envelope method," Gan To Kagaku Ryoho, 10: 1146-1159	
	111	NAKAZATO et al., 1994, "Efficacy of immunotherapy as adjuvant treatment after curative resection of gastric cancer," The Lancet, 343:1122-1126	
	112	HIROAKI NANBA and KEIKO KUBO, 1997, "Effect of Maitake D-Fraction on Cancer Prevention," Annals. N.Y. Acad. Sci. 833:204-207	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
† Applicant's unique citation designation number (optional). ‡ Applicant is to place a check mark here if English language Translation is attached.  
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 10 of 12

**Complete if Known**

Application Number	10/565,484
Filing Date	January 17, 2006
First Named Inventor	CHEUNG, Nai-Kong V.
Art Unit	1623
Examiner Name	Eric Olson
Attorney Docket Number	639-C-PCT-US

**OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	113	NICOLOSI et al., 1999, "Plasma lipid changes after supplementation with $\beta$ -glucan fiber from yeast," Am. J. Clin. Nutr., 70:208-212	
	114	OHNO et al., 2000, "Antitumor 1,3- $\beta$ -Glucan from Cultured Fruit Body of Sparassis crispa," Biol. Pharm. Bull., 23(7):866-872	
	115	OLLERT et al., April 1996, "Normal human serum contains a natural IgM antibody cytotoxic for human neuroblastoma cells," Proc. Natl. Acad. Sci. USA, 93:4498-4503	
	116	OLLERT et al., October 1997, "Mechanisms of in vivo antineuroblastoma activity of human natural IgM," European Journal of Cancer, 33(12):1942-1948	
	117	ONIZUKA et al., July 1, 1999, "Tumor Rejected by in Vivo Administration of Anti-CD25 (Interleukin-2 Receptor $\alpha$ ) Monoclonal Antibody," Cancer Research, 59:3128-3133	
	118	OXFORD TEXTBOOK OF ONCOLOGY, 1995, "Chemotherapy: General Aspects", Peckham, Pinedo and Veronesi, ed., Vol. 1, 447-453	
	119	PATCHEN et al., 1984, "Soluble Polyglycans Enhance Recovery from Cobalt-60-Induced Hemopoietic Injury", Journal of Biological Response Modifiers, 3:627-633	
	120	PEAT et al., 1958, "Polysaccharides of Baker's Yeast. Part II. Yeast Glucan", Journal Chem. Soc. Part 1, 3862-3868	
	121	RAI, K.R. and GUPTA, N., June 2000, "Monoclonal Antibodies in Chronic Lymphocytic Leukemia," Rev. Clin. Exp. Hematol., 4:2:134-144	
	122	REN et al., 1997, "Mechanisms of Anti-Lung Cancer Activity for Monoclonal Antibody to Epidermal Growth Factor Receptor," Disi Junyi Daxue Xuebao, 18(6):560-562 (abstract only)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

†Applicant's unique citation designation number (optional). ‡Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/565,484
Filing Date	January 17, 2006
First Named Inventor	CHEUNG, Nai-Kong V.
Art Unit	1623
Examiner Name	Eric Olson
Attorney Docket Number	639-C-PCT-US

Sheet

11

of

12

## OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	123	ROBBINS et al., 1977, "Cholesterol Lowering Effect of Dietary Yeast and Yeast Fractions", Journal of Food Science, 42 (3):694-698	
	124	SAITO et al., 1977, "A C-N.M.R.-spectral study of a gel forming, branched (1-3)-β-D-Glucan, (Lentinan) from Lentinus edodes, and its acid-degraded fractions. Structure, and Dependence of Confirmation on the Molecular Weight", Carbohydrate Research, 58:293-305	
	125	SASAKI et al., 1976, "Antitumor Activity of Degraded Products of Lentinan: It's Correlation with Molecular Weight", Gann, 67:191-195	
	126	SELJELID et al., 1977, "Glycan Stimulation of Macrophages in Vitro", Experimental Cell Research, 131:121-129	
	127	SELJELID et al., 1986, "A water soluble aminated β-1,3-D-glucose derivative caused regression of solid tumors in mice", Bioscience Reports 6:845-852	
	128	SINGH et al., 1974, "Scleroglucan, an antitumor polysaccharide from Sclerotium glaucanicum", Carbohydrate Research, 37:245-247	
	129	SLOVIN, S.F. et al., May 1999, "Carbohydrate vaccines in cancer: Immunogenicity of a fully synthetic globa H hexasaccharide conjugate in man," Proc. Natl. Acad. Sci. USA, 96:5710-5715	
	130	SOIFFER et al., 1997, "Administration of R24 Monoclonal Antibody and Low-Dose Interleukin 2 for Malignant Melanoma," Clinical Cancer Research, 3:17-24	
	131	SONG et al., "Yeast glucan and immunotherapy of infectious diseases", Yeast glucan and immunotherapy, chapter 18, 533-545	
	132	TORISU et al., 1990, "Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancer," Cancer Immunology Immunotherapy, 31 (5):261-268	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTC

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

12

of

12

Application Number

10/565 484

Filing Date

January 17, 2006

**First Named Inventor**

CHEUNG, Nai-Kong V.

### Art Unit

1623

Examiner Name \_\_\_\_\_

Eric Olson

Attorney Docket Number

639-C-PCT-US

## OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

[illegible]

Examiner  
Signature

Date \_\_\_\_\_

Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**1** Applicant's unique citation designation number (optional). **2** Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*